Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Journal of hepatology - 1 Sept 2012

Ono Atsushi, Suzuki Fumitaka, Kawamura Yusuke, Sezaki Hitomi, Hosaka Tetsuya, Akuta Norio, Kobayashi Masahiro, Suzuki Yoshiyuki, Saitou Satoshi, Arase Yasuji, Ikeda Kenji, Kobayashi Mariko, Watahiki Sachiyo, Mineta Rie, Kumada Hiromitsu

Abstract excerpt

BACKGROUND & AIMS: We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection. METHODS: The cumulative rates of undetectable hepatitis B virus DNA (HBV DNA;<2.6 log(10) copies/ml), hepatitis B e antigen (HBeAg) seronegativity, seroconversion, alanine aminotransferase (ALT) normalization, and entecavir signature...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Kaplan-Meier Estimate

Share to Multivariate Analysis

Source

Identifiers

PMID: 22659518
DOI: 10.1016/j.jhep.2012.04.037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.PMID 22659518Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.Semantic proximity Read ↗

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.Semantic proximity Read ↗

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients.Semantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.Semantic proximity Read ↗

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Semantic proximity Read ↗

Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.Semantic proximity Read ↗

Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.